连亏四年 南新制药豪赌重组

Core Viewpoint - Nanjing Pharmaceutical (688189) has faced continuous losses for four years since its IPO and is now planning a restructuring to seek new profit growth points [1][8] Group 1: Restructuring and Acquisition - Nanjing Pharmaceutical intends to acquire a group of assets from Future Medicine through cash, with a total estimated transaction price not exceeding 480 million yuan [1][6] - The acquisition includes products such as "Multiple Trace Element Injection (I)" and "Multiple Trace Element Injection (II)", which are listed under the national medical insurance category [3][4] - The acquisition is expected to enhance the company's product pipeline and align with its "health management" strategy [5][9] Group 2: Financial Performance - Nanjing Pharmaceutical has reported continuous net losses since its IPO, with net profits of approximately -162 million yuan, -79 million yuan, -11 million yuan, and -357 million yuan from 2021 to 2024 [8] - The company's revenue for the same period was approximately 744 million yuan, 699 million yuan, 720 million yuan, and 263 million yuan [8] - The company has acknowledged that its main business has been affected by industry policies and increased market competition, leading to adjustments in sales strategies and price reductions [9] Group 3: Market Reaction - Following the announcement of the restructuring, Nanjing Pharmaceutical's stock price surged by 20%, reaching a closing price of 16.98 yuan per share on August 27 [2][3] - The trading volume on that day was 418 million yuan, with a turnover rate of 9.32% and a total market capitalization of 4.659 billion yuan [3]